|Bid||0.00 x 1100|
|Ask||65.77 x 1400|
|Day's Range||64.30 - 65.55|
|52 Week Range||60.14 - 83.88|
|Beta (3Y Monthly)||1.30|
|PE Ratio (TTM)||21.55|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||2.00 (3.16%)|
|1y Target Est||89.57|
Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included a top automaker and a leading airline. Bearish calls included a troubled utility and a video game ...
U.S. debt ceiling? China trade? Brexit? All of this would seem to put stocks at elevated risk of a crash. But we’ve already had our crash—and that bodes well for what comes next.
CVS Health Corp. and Walmart Inc. settled their fight over the cost of filling prescriptions, averting a threatened split between the health-care giant and the retail behemoth. CVS had said Monday that Walmart was expected to leave drugstore networks of its pharmacy-benefit manager, CVS Caremark. The move would have affected people whose employers have CVS Caremark-administered drug benefits, as well as Medicaid enrollees with CVS drug coverage.
to maintain its retail pharmacy Medicaid network and pharmacy benefit management systems after warning earlier this week that the two companies had parted ways. CVS had argued that Walmart's required rates to maintain the system would result in higher drug prices for customers, but noted Friday that the two sides had reached a "a mutually agreeable solution", although terms of the deal were not disclosed. "We are pleased to have reached fair and equitable terms with CVS Caremark that are in the best interest of our customers, and we are glad our CVS Caremark customers will be able to continue saving money and living better," said Walmart senior vice president Sean Slovenski.
Stocks that moved substantially or traded heavily on Friday: V.F. Corp., up $9.08 to $82.34 The maker of brands including Timberland and North Face raised its forecasts following a strong quarter. Tesla ...
Walmart, CVS, American Express, Apple, Johnson & Johnson, Rio Tinto and Tribune Publishing are the companies to watch.
Hints of China trade progress sent U.S. stocks and global markets higher Friday, but Netflix and Tesla posted heavy losses, hampering early gains.
Walmart Inc (NYSE: WMT ) announced Friday a multi-year agreement to remain in the CVS Health Corp (NYSE: CVS ) Caremark pharmacy benefit management program and Managed Medicaid retail pharmacy network. ...
On Tuesday, CVS said the companies had failed to agree on pricing and that Walmart was leaving the pharmacy network for prescription drug plans that CVS manages for companies and health insurers and for the government-run Medicaid program for low-income people. Walmart and CVS also said on Tuesday they were still in discussions. "We view the agreement positively for CVS," Cantor Fitzgerald analyst Steven Halper said in a research note, explaining that the loss of Walmart pharmacies could have negatively impacted CVS' ability to sign up customers for its 2020 prescription drug plans.
The stock had been under pressure since Tuesday, when it said it could not come to an agreement with Walmart on pricing. CVS executive Derica Rice said in a statement Friday that the companies had reached a "mutually agreeable solution" that would allow customers with pharmacy benefits managed by CVS Health's Caremark business to still have their prescriptions filled at Walmart locations.
On Tuesday, CVS said the companies had failed to agree on pricing and that Walmart was leaving the pharmacy network for the prescription drug plans that CVS manages for companies and health insurers and for the Medicaid program for low income people. "We view the agreement positively for CVS," Cantor Fitzgerald analyst Steven Halper said in a research note, explaining that the loss of Walmart pharmacies could have negatively impacted CVS' ability to sign customers for its 2020 prescription drug plans.
Shares of CVS Health Corp. rallied 2.6% in premarket trade Friday, after the drugstore chain and Walmart Inc. have reached a multi-year agreement in which Walmart will continue to participate in the CVS Caremark pharmacy benefit management (PBM) retail pharmacy networks. Walmart shares were still inactive. The companies did not disclose financial terms of the agreement. Earlier this week, CVS said Walmart had decided to leave its PBM networks because of a dispute over pricing. "We are very pleased to have reached a mutually agreeable solution with Walmart. As a PBM, our top priority is to help our clients and consumers lower their pharmacy costs," said CVS Caremark President Derica Rice. "This new agreement accomplishes our top priority and enables Walmart to continue participating in CVS Caremark's commercial and Managed Medicaid pharmacy networks and provides enhanced network stability for our clients and their members." CVS's stock has tumbled 15% over the past three months through Thursday, while Walmart shares have gained 0.6% and the Dow Jones Industrial Average has slipped 4.0%.
Walmart to Continue Participating in CVS Caremark Commercial and Managed Medicaid Retail Pharmacy Networks Walmart also remains in CVS Caremark Medicare Part D networks WOONSOCKET, R.I. and BENTONVILLE, ...
UnitedHealth Group (NYSE:UNH) erased around half of its losses from the December 2018-January 2019 period. Just as markets often get it wrong, it did so again with UNH stock when the company reported strong quarterly reports. With a proven management team, the company has a multiyear growth plan that embraces digitalization. So as UnitedHealth continues to cut costs, operate more effectively and increase revenue, investors will get rewarded. ### UnitedHealth's Fourth-Quarter Results UnitedHealth reported GAAP EPS of $3.10 as revenue grew 12.2% to $58.42 billion. Both figures easily beat the street estimates. Its quarterly results surpassed its own previous forecast, communicated at its Investor Conference outlook meeting. Optum's earnings pulled out ahead because of overall medical cost controls. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Management successfully tackled expenses by executing on both structural costs and rate recovery. This sets up for an even better 2019 performance. * 7 Stocks to Buy as the Dollar Weakens UNH stock is still around 10% below its 52-week high. And at a valuation of 15.6 times forward earnings, the stock may have more upside potential due to the outsized growth. Digitalization, or linking physical interactions to digital channels supported by proprietary data analytics, is already improving performance. The platform already has 22 million registered users that the company may engage with to deliver better service on health promotion and its related finances. The improved interactions between patients and the company will continue to drive profit growth higher. For example, pharmacy care services reported a 98% retention rate. It won new business awards from health plans and employer plans, which already sets the company up for 2020 revenue growth. It is looking more likely that the 15.6 times forward P/E is too low and does not reflect the company's upside over the next few years. ### Growth Drivers for UNH Stock UnitedHealth's two drivers for justifying a higher share price is simple. Lower total medical costs will continue and revenue will go up. Both are connected: by keeping people healthier and avoiding unnecessary hospital visits, costs go down. Commercial customers like this pattern and also join UNH. Looking beyond into 2030, when 80 million people in the U.S. will have three or more chronic conditions, up from 30 million in 2015, it is imperative that UnitedHealth builds its comprehensive portfolio of care delivery services. On the back end, data analytics across all of Optum will help UNH reduce costs while delivering better care to its customers. ### Risks for UnitedHealthcare Ignoring the potential and actual risks in investing in UNH stock would give an incomplete picture to readers. Management expects a health insurance tax will come back in 2020. This will also increase healthcare costs by $20 billion for the 142 million Americans. At $500 in extra costs per family with small business coverage, the customer acquisition rate UNH enjoys today may slow because of this. Despite the headwinds coming up, UnitedHealth will soon realize the benefits of winning a few large corporate deals. In 2020, it will focus more on health plans and then the large employer group. ### Valuation 13 analysts on Wall Street cover UnitedHealth stock and on average, have a $308.90 price target. Every single analyst report in the last month is a "buy" call: Analyst Firm Position Price Target Action Date John Ransom Raymond James Buy $310.00 Reiterated 1 day ago Kevin Fischbeck Merrill Lynch Buy $320.00 Reiterated 1 day ago Michael Wiederhorn Oppenheimer Buy $305.00 Reiterated 2 days ago Sarah James Piper Jaffray Buy -- Reiterated 2 days ago Steven Halper Cantor Fitzgerald Buy $310.00 Reiterated 2 days ago Ana Gupte Leerink Partners Buy $335.00 Reiterated 2 days ago A.J. Rice Credit Suisse Buy $310.00 Reiterated 3 days ago Steve Willoughby Cleveland Research Buy -- Reiterated 6 days ago Steven Valiquette Barclays Buy $279.00 Reiterated 13 days ago Zachary Sopcak Morgan Stanley Buy $315.00 Reiterated Last month David Toung Argus Research Buy $295.00 Reiterated Last m Source: tipranks Investors may have a contrarian viewpoint against Wall Street reports but it is hard to get negative on UNH stock after its Q4 results. Overall, UnitedHealth looks like a slow and steady climber whose stock will reward patient investors. ### Related Investment CVS Health Corporation (NYSE: CVS) is embracing the PBM model through its Express Scripts acquisition. The stock trades at 8.4 times forward P/E and is barely above 52-week lows. Investors are punishing the stock and pricing in the integration risks related to the acquisition. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Growth Stocks With the Future Written All Over Them * 7 Reasons Why Buffett's Bet on Apple Stock Is a Good One * 10 Companies That Could Post Decelerating Profits Compare Brokers The post UnitedHealth Is a Steady Investment for the Patient Investor appeared first on InvestorPlace.
Healthcare stocks cover a wide range of equities. Pharmaceuticals, equipment providers, insurers, pharmacies, technology, and even healthcare-related real estate investment trusts (REIT) can all fall under this category. However, these companies all benefit from the same trends. The share of healthcare in the overall U.S. economy continues to grow. The Centers for Medicare and Medicaid Services (CMS) estimates that healthcare encompasses about 17.9% of the U.S. economy. Moreover, with an estimated 10,000 baby boomers aging into Medicare a day, the pressure on limited healthcare resources continues to mount. * 7 Oversold Small-Cap Stocks With Massive Profit Growth While this can mean pain for the healthcare consumer, it can also bring benefit to those who invest in healthcare. With more of the baby boom generation on Medicare, a larger percentage of the population benefits from a healthcare subsidy. This gives a noticeable boost to healthcare stocks. Here are three that could help you benefit from this trend. InvestorPlace - Stock Market News, Stock Advice & Trading Tips ### AbbVie (ABBV) Source: Shutterstock Few healthcare stocks find themselves in a better position for both income and growth potential than AbbVie (NYSE:ABBV). Abbott Laboratories (NYSE:ABT) created AbbVie when it spun off its pharmaceutical division in 2013. After a growth spurt in 2017, ABBV fell as concerns about patent expirations on its blockbuster drug Humira weighed on the stock. Today it trades at about 30% below its 52-week high. However, ABBV stock also looks well-positioned to make a comeback. The Humira-driven swoon in ABBV has taken the forward P/E ratio to around 9.8. This comes in well below the average P/E of 18.2 over the last five years. Moreover, Evaluate Pharma ranks AbbVie's drug pipeline as second-best in the industry for value creation. Also, the company has time to transition to its next high-revenue drug. It will hold a patent on Humira in the U.S. until at least 2022. Analysts also do not seem worried as they predict profit growth of almost 10% per year through at least 2021. Furthermore, Wall Street considers AbbVie a dividend aristocrat due to its previous ties to Abbott. As a result, the company faces tremendous pressure to increase its dividend annually. AbbVie increased its payout from $3.59 per share to $4.28 per share this year. Hence, despite a generous yield of almost 4.9%, investors can probably expect annual increases in future years. Also, I see this massive dividend increase as a vote of confidence in itself. Couple that with the low P/E and the high ratings that AbbVie's drug pipeline has received, and ABBV should be one of the few healthcare stocks which will outperform in both the growth and income categories. ### Teladoc Health (TDOC) Source: MayApps207 via WikiMedia Buying Teladoc Health (NYSE:TDOC) amounts to buying into the future of healthcare. Without a doubt, the 17.9% of the economy that healthcare now consumes weighs heavily on family budgets. Teladoc allows patients to see a licensed doctor at any time via a PC or mobile device, reducing the need to take time off from work. It also saves money as visits can run as low as $40. Telehealth has only begun to realize its potential. Analysts estimate telehealth can handle about one-third of the 1.25 billion office visits that take place each year in the U.S. With Teladoc handling an estimated two million visits in 2018, the company still covers less than 1% of its potential market. Teladoc also shows that it can acquire the right partners to improve its quality and reach more patients. It widened its competitive moat by investing in diagnostic capabilities with a takeover of Best Doctors. It also partnered with CVS Health (NYSE:CVS) to provide care to its customers. Additionally, it boosted its offshore footprint by buying Advance Medical. Advance Medical was the leading telehealth provider outside the U.S. before TDOC purchased the company. Investors should note that TDOC remains expensive. Its price in the $55 per share range places it at around 9.3 times sales. Still, it has fallen almost 40% from its October high. Also, revenue grew by 78% in 2018. Although that growth will fall over time, analysts estimate that the company will turn profitable in 2021. * 10 Growth Stocks With the Future Written All Over Them Teladoc remains one of the more speculative healthcare stocks. However, with a $3.8 billion market cap, and a majority market share in a business that has reached less than one percent of its full potential, Teladoc could become one of the best stocks in healthcare. ### Dentsply Sirona (XRAY) Source: Shutterstock An aging population creates an increasing need for dental care and the equipment provided by Dentsply Sirona (NASDAQ:XRAY). As the ticker implies, Dentsply manufactures dental imaging equipment as well as consumable supplies and specialty dental products. Medicare rarely covers dental needs. However, many consumers place a high value on having a beautiful smile and the ability to chew food. Hence, most customers will spend money on services requiring XRAY's supplies and equipment. This also holds true outside of the U.S. Dentsply Sirona conducts business in over 120 countries. These other countries account for about 65% of the company's revenue. XRAY stock rose steadily between 2009 and 2018. However, in 2018, the stock lost almost half of its value. By late October, it traded as low as $33.93 per share, a level first seen in 2011. The stock sold off for most of the year on lower-than-expected sales. An impairment charge on goodwill and intangible assets in the second quarter hurt earnings. The stock fell by nearly 20% on August 7 following this announcement. However, management responded with a restructuring plan. While that breeds uncertainty, the forecasts indicate an opportunity for buyers. The forward P/E ratio stands at around 18, well below the five-year average of 28.1. Furthermore, analysts predict 11.2% consensus profit growth this year. They also foresee double-digit profit increases through at least 2021. XRAY faced a great deal of pain in 2018. Still, the need for dental supplies and equipment will only rise in the coming years. For this reason, the lower multiple and the predicted profit growth should bring about a recovery in Dentsply Sirona. As of this writing, Will Healy is long TDOC stock. You can follow Will on Twitter at @HealyWriting. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Top 10 Global Stock Ideas for 2019 From RBC Capital * 10 A-Rated Stocks the Smart Money Is Piling Into * 5 Best Bank ETFs for This Week's Earnings Avalanche Compare Brokers The post 3 Healthcare Stocks That Will Keep Your Portfolio Healthy appeared first on InvestorPlace.
While Amazon is figuring out ways to expand in the multibillion dollar pharmacy industry, Walgreens and other industry players are ready to counter competition.
CVS Health Corp. is battling Walmart Inc. over the cost of filling prescriptions, a clash that could result in a split between the retail behemoth and the health-care giant. Walmart is expected to leave CVS Caremark pharmacy networks over the dispute, a split that could occur as soon as early February, though CVS said it has asked for an extension through April 30. CVS Caremark, the pharmacy-benefits unit of CVS Health, said Monday that Walmart is seeking an increase in what the retailer gets paid for prescriptions, which would “ultimately result in higher costs for our clients and consumers.” CVS Caremark, which is separate from CVS’s retail drugstores, reimburses pharmacies when shoppers with CVS Caremark prescription coverage buy medicine.
Compensation Advisory Partners Associate Ryan Colucci and Founding Partner Melissa Burek By John Jannarone 100x? 1000x? The ratio of CEO compensation to median employee income can be a staggering figure – one that some companies feared would cause uproar among staff and journalists when they were widely reported in public filings over the last year. […]
Jim Cramer says the move would boost Apple's stock price and give the company a surefire way to solidify its place in the health-care arena.